Top Breast Cancer News of 2016

Slideshow

This slide show highlights some of the top breast cancer news of 2016, including a study looking at optimal margins in DCIS, a trial on biosimilars, a new FDA approval, and more.

Recent Videos
Regardless of disease burden or disease progression speed on front-line therapy, trastuzumab deruxtecan appears effective in HER2-low breast cancer.
Performance status, age, and comorbidities may impact benefit seen with immunotherapy vs chemotherapy in patients with breast cancer.
Related Content
Data from analytical similarity studies and comparative clinical trials support the application of HLX11 in HER2-positive breast cancer.

FDA Accepts BLA for Pertuzumab Biosimilar in HER2+ Breast Cancer

Russ Conroy
February 4th 2025
Article

Data from analytical similarity studies and comparative clinical trials support the application of HLX11 in HER2-positive breast cancer.

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

Paolo Tarantino, MD;Matteo Lambertini, MD
January 13th 2025
Podcast

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

New AI Technology May Have the Potential to Optimize Cancer Surgery

New AI Technology May Have the Potential to Optimize Cancer Surgery

Tim Cortese
February 3rd 2025
Article

Anant Madabhushi, PhD, and Farzad Fereidouni, PhD, are developing the MarginCall technology to reduce time lag and improve tumor margin assessment accuracy in breast and ovarian cancer surgery.

A study evaluating disparities in breast reconstructive surgery sought to assess the impact of culture, race, and ethnicity in minority groups.

Reducing Post-Mastectomy Disparities in Breast Cancer Minority Populations

Rachel A. Greenup, MD, MPH
December 23rd 2024
Podcast

A study evaluating disparities in breast reconstructive surgery sought to assess the impact of culture, race, and ethnicity in minority groups.

Tucatinib plus trastuzumab was well tolerated in patients with metastatic breast cancer and consistent with the combination’s established safety profile.

Tucatinib Combo Shows Meaningful Activity in HER2+ Metastatic Breast Cancer

Roman Fabbricatore
January 30th 2025
Article

Tucatinib plus trastuzumab was well tolerated in patients with metastatic breast cancer and consistent with the combination’s established safety profile.

Inavolisib Combo Meets OS End Point in PIK3CA+ Metastatic Breast Cancer

Inavolisib Combo Meets OS End Point in PIK3CA+ Metastatic Breast Cancer

Tim Cortese
January 28th 2025
Article

The phase 3 INAVO120 trial reported statistically significant OS results in patients with PIK3CA-mutant, locally advanced or metastatic breast cancer.